Hangzhou Huqingyu Hall Pharmaceutical Co., Ltd., Hangzhou, China.
Tongde Hospital of Zhejiang Province, Hangzhou, China.
J Ethnopharmacol. 2024 Nov 15;334:118538. doi: 10.1016/j.jep.2024.118538. Epub 2024 Jul 9.
Weifuchun (WFC) is a Traditional Chinese Medicine commonly used for treating atrophic gastritis and intestinal metaplasia. Till date, its antitumor effect on gastric cancer (GC) and the underlying mechanisms of the effect remains unelucidated.
We aim to investigate if WFC can suppress the malignancy of stomach cancer cells and dissect the molecular basis and the associated molecular and cellular features.
Stomach cancer cell lines and normal gastric epithelial cells were treated with WFC. CCK8 assay, caspase-3 activity assay, adhesion assay, microRNA database analysis, transfection, RT-PCR, Western Blotting, signaling pathway analysis, and in vivo GC model were employed to examine the changes in the features of the gastric cancer cells and the molecular mechanisms of the effect of WFC.
Here we present data demonstrating that WFC suppresses the malignant cellular phenotypes of GC and this inhibitory effect is mediated by downregulating the expression of oncogenic KPNA2. Furthermore, WFC downregulates KPNA2 through miR-26a-5p-mediated gene silencing and the deactivated phosphorylation dynamics of mitogen-activated protein kinase (MAPK). The suppressive effect of WFC on stomach cancer cell behavior was further confirmed in animal model.
Therefore, WFC can exert inhibitory effect on the malignancy of GC cells by reducing the levels of KPNA2. Moreover, the miR-26a-5p rescue and the deactivation MAPK pathway induced by WFC result in the downregulation of KPNA2 expression. Thus, our findings suggest WFC as a potential treatment option against GC.
胃复春(WFC)是一种常用于治疗萎缩性胃炎和肠上皮化生的中药。迄今为止,其对胃癌(GC)的抗肿瘤作用及其作用机制仍不清楚。
本研究旨在探讨 WFC 是否能抑制胃癌细胞的恶性程度,并剖析其作用的分子基础及相关的分子和细胞特征。
用 WFC 处理胃癌细胞系和正常胃上皮细胞。采用 CCK8 检测试剂盒、caspase-3 活性检测试剂盒、黏附实验、microRNA 数据库分析、转染、RT-PCR、Western Blotting、信号通路分析和体内 GC 模型,检测胃癌细胞特征的变化以及 WFC 作用的分子机制。
本研究提供的数据表明,WFC 抑制 GC 的恶性细胞表型,这种抑制作用是通过下调致癌基因 KPNA2 的表达介导的。此外,WFC 通过 miR-26a-5p 介导的基因沉默和有丝分裂原激活蛋白激酶(MAPK)的失活磷酸化动力学下调 KPNA2。WFC 对胃癌细胞行为的抑制作用在动物模型中得到进一步证实。
因此,WFC 通过降低 KPNA2 的水平对 GC 细胞的恶性程度发挥抑制作用。此外,WFC 诱导的 miR-26a-5p 恢复和 MAPK 通路失活导致 KPNA2 表达下调。因此,我们的研究结果表明 WFC 可能是治疗 GC 的一种潜在选择。